Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. (Q53928855)

22 May 2018

title

Comparison of immunogenicity of two hepatitis A vaccines--VAQTA and HAVRIX--in young adults. (English)

1 reference

22 May 2018

1 reference

Ashur Y

1

1 reference

22 May 2018

Adler R

series ordinal

2

1 reference

22 May 2018

Rowe M

series ordinal

3

1 reference

22 May 2018

Shouval D

series ordinal

4

1 reference

22 May 2018

language of work or name

English

0 references

publication date

1 May 1999

1 reference

22 May 2018

published in

Vaccine

1 reference

22 May 2018

volume

17

1 reference

22 May 2018

issue

18

1 reference

22 May 2018

page(s)

2290-2296

1 reference

22 May 2018

An Inactivated Hepatitis A Virus Vaccine Prepared from Infected Marmoset Liver

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Approaches to a vaccine against hepatitis A: development and manufacture of an inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Protection against hepatitis A by an inactivated vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Immunologic approaches to assessing the response to inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Sensitive assays for hepatitis A antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Immunogenicity of a killed hepatitis A vaccine in seronegative volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Time course of hepatitis A virus antibody titer after active and passive immunization

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

A single vaccination with an inactivated hepatitis A liposome vaccine induces protective antibodies after only two weeks

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Inactivated virosome hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Primary study of attenuated live hepatitis A vaccine (H2 strain) in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Inactivated hepatitis A vaccine: active and passive immunoprophylaxis in chimpanzees

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Clinical experience with an inactivated hepatitis A vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

The three-year incidence of non-B viral hepatitis morbidity in a controlled trial of pre-exposure immune serum globulin prophylaxis

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Host immune response to hepatitis A virus.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Immunoprecipitation and virus neutralization assays demonstrate qualitative differences between protective antibody responses to inactivated hepatitis A vaccine and passive immunization with immune globulin

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Estimated persistence of anti-HAV antibodies after single dose and booster hepatitis A vaccination (0-6 schedule).

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Persistence of antibodies after inactivated hepatitis A vaccines in a comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Simultaneous active and passive immunization against hepatitis A studied in a population of travellers

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

Depression of the immune response to an inactivated hepatitis A vaccine administered concomitantly with immune globulin.

1 reference

https://api.crossref.org/works/10.1016%2FS0264-410X%2898%2900480-0

7 January 2021

10.1016/S0264-410X(98)00480-0

Identifiers

DOI

1 reference

22 May 2018

1 reference

22 May 2018